CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

Cancer Research and Treatment. 2019;51(2):718-726. Published online 2018 September 3 DOI: https://doi.org/10.4143/crt.2018.324

Cancer Research and Treatment. 2019;51(2):718-726

Link1

Link2 Link3

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs

Su Jin Lee, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

Lung Cancer. 2015;90(2):261-266

Link1 Link2

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

Nabil Mubarak, Rabab Gaafar, Samir Shehata, Tarek Hashem, Dani Abigeres, Hamdy A Azim, Gamal El-Husseiny, Hamed Al-Husaini, Zhixin Liu

BMC Cancer. 2012;12(1):

Link1

Link2 Link3

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations

Sehhoon Park, Bhumsuk Keam, Se Hyun Kim, Ki Hwan Kim, Yu Jung Kim, Jin-Soo Kim, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo

Cancer Research and Treatment. 2015;47(4):630-637

Link1

Link2 Link3

Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE)

Domenico Galetta, Salvatore Pisconti, Saverio Cinieri, Giovanni Luigi Pappagallo, Vittorio Gebbia, Nicola Borsellino, Evaristo Maiello, Antonio Rinaldi, Michele Montrone, Pietro Rizzo, Nicola Marzano, Nicola Sasso, Antonio Febbraro, Giuseppe Colucci

Clinical Lung Cancer. 2011;12(6):402-406

Link1 Link2

Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study

Y. Tsutani, Y. Miyata, T. Masuda, K. Fujitaka, M. Doi, Y. Awaya, S. Kuyama, S. Kitaguchi, K. Ueda, M. Okada

Annals of Oncology. 2017;28:x137

Link1 Link2 Link3

Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer

Toshirou Fukushima, Yuuki Wakatsuki, Takashi Kobayashi, Kei Sonehara, Kazunari Tateishi, Manabu Yamamoto, Takeshi Masubuchi, Fumiaki Yoshiike, Kazuya Hirai, Tsutomu Hachiya, Tomonobu Koizumi

Cancer Chemotherapy and Pharmacology. 2018;81(6):1043-1050

Link1 Link2

Link3

Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review

Han Bao Hui, Lu Lu Yang, Xin Wang, Luan Di Yao

OncoTargets and Therapy. 2018;Volume 11:2121-2129

Link1 Link2

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors

Zhansheng Jiang, Yu Zhang, Yinli Yang, Zhensong Yue, Zhanyu Pan

Thoracic Cancer. 2018;9(9):1151-1155

Link1 Link2

PCN17 Indirect Comparison of the Efficacy of Erlotinib Versus Pemetrexed Plus Cisplatin as First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations

C. Pereira, M. Sanches, J.F. Loff

Value in Health. 2012;15(7):A411-A412

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.